Suprax Shortage: What Providers and Prescribers Need to Know in 2026

Cefixime (Suprax), a third-generation oral cephalosporin with a well-established role in outpatient infectious disease management, has become increasingly difficult for patients to locate at retail pharmacies. While not currently listed on the FDA or ASHP drug shortage databases, practical access barriers — limited manufacturers, inconsistent pharmacy stocking, and supply chain fragility — are causing patient-level dispensing delays. This briefing covers the current supply landscape, prescribing implications, cost and access considerations, and tools available to help your patients fill their prescriptions.

Current Supply Status (Q1 2026)

As of Q1 2026, cefixime is not on the FDA Drug Shortages list or the ASHP Current Shortages list. However, anecdotal and patient-reported data suggest inconsistent availability at the pharmacy level, particularly at large chain pharmacies.

Cefixime was FDA-approved in 1989 and has been available generically since its patent expiration. The drug's US market history includes a notable disruption: brand-name Suprax was withdrawn from the market in 2002 by Wyeth and subsequently reintroduced in 2004 by Lupin Pharmaceuticals. Currently, generic cefixime is manufactured primarily by Lupin Pharmaceuticals and Aurobindo Pharma. This limited manufacturer base creates vulnerability — a production delay or quality hold at either facility can significantly impact national supply. The broader context of global antibiotic API sourcing adds additional risk, as most active ingredients are manufactured overseas.

Pharmacy-Level Availability Landscape

Understanding where patients are most likely to successfully fill their prescriptions helps direct them more efficiently:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Inconsistent stocking. Many locations do not routinely stock cefixime, ordering on demand instead. This creates 1–2 day delays for patients.
• Independent pharmacies: Generally better availability due to multiple wholesaler relationships and more responsive ordering practices. First recommendation for patients.
• Hospital outpatient pharmacies: May have better supply through hospital-specific distribution channels.
• Mail-order pharmacies: Amazon Pharmacy and Cost Plus Drugs may carry generic cefixime, though shipping timelines (2–5 days) make this less suitable for acute infections.

Clinical Indications and Prescribing Considerations

Cefixime (Suprax) is FDA-approved for adults and pediatric patients ≥6 months for the following indications:

• Uncomplicated UTIs caused by E. coli and Proteus mirabilis
• Otitis media caused by H. influenzae, Moraxella catarrhalis, and S. pyogenes
• Pharyngitis and tonsillitis caused by S. pyogenes (note: penicillin remains drug of choice)
• Acute exacerbations of chronic bronchitis
• Uncomplicated cervical/urethral gonorrhea caused by N. gonorrhoeae (note: CDC now recommends ceftriaxone IM as first-line)

Key prescribing note: Standard adult dosing is 400 mg daily as a single dose or 200 mg twice daily. Pediatric dosing is 8 mg/kg/day (max 400 mg/day). Dose reduction is required for creatinine clearance below 60 mL/min. For otitis media, prescribe the chewable tablet or suspension — not the tablet or capsule — due to higher serum concentrations achieved.

Evidence-Based Alternatives by Indication

When cefixime is unavailable, the following alternatives are evidence-based and widely stocked:

• UTIs: Cefpodoxime 100 mg BID x 7 days (most similar pharmacologically), nitrofurantoin 100 mg BID x 5 days (uncomplicated only), or TMP-SMX DS BID x 3 days (check local resistance rates)
• Otitis media: Amoxicillin 80–90 mg/kg/day (first-line per AAP); amoxicillin-clavulanate or cefdinir for treatment failures or penicillin allergy
• Pharyngitis: Penicillin V or amoxicillin (first-line); azithromycin for penicillin allergy (note increasing Group A Strep resistance)
• Bronchitis exacerbations: Azithromycin, doxycycline, or amoxicillin-clavulanate depending on severity and suspected pathogen
• Gonorrhea: Ceftriaxone 500 mg IM single dose (CDC-preferred first-line; cefixime is no longer recommended as first-line due to concerns about susceptibility)

Cost and Access Considerations for Your Patients

Cost often contributes to non-adherence. Sharing these specifics with patients can improve outcomes:

• Generic cefixime cash price: $50–$85 for a standard course; as low as $14.18 with SingleCare or GoodRx discount cards
• Brand Suprax: $150–$252+ cash; no manufacturer copay card currently available for generic cefixime
• Insurance: Generic typically on Tier 2; copay $5–$30 for most commercial plans. Medicare Part D generally covers generic cefixime.
• Patient assistance: Prescription Hope offers Suprax at $70/month for qualifying patients through manufacturer programs. NeedyMeds.org lists additional resources.

Tools to Help Your Patients Find Suprax

Direct patients to medfinder.com/providers to check real-time pharmacy stock in your patient's area. medfinder calls pharmacies near the patient to verify which ones have their medication in stock, then texts the patient results. This can be integrated into your prescribing workflow before the patient leaves the clinic, reducing downstream medication access failures.

See also: How to Help Your Patients Find Suprax in Stock: A Provider's Guide